Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Apr 10;60(Suppl 1):S20–S29. doi: 10.1093/cid/ciu1175

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — The estimated epidemic curve without vaccination and the cumulative number of persons protected by an influenza vaccination program with the following assumptions: an overall clinical attack rate of the influenza pandemic of 20% or 30%; administered 10 million (left) or 30 million (right) vaccine doses; vaccination programs that begin 8 or 16 weeks before, the same week, or 8 or 16 weeks after the first cases of a novel influenza virus occur in the United States (US); and the vaccine effectiveness (VE) equivalent to the H1N1pmd09 monovalent vaccine. 2009 H1N1-like VE: 2 doses of vaccine administered 3 weeks apart required to be fully effective (62% for persons aged <60 years and 43% for persons ≥60 years) in protecting against subclinical and clinical cases, hospitalizations, and deaths. We assumed 1 dose of vaccine to be 0% effective for all age groups.